share_log

Investing in IDEXX Laboratories (NASDAQ:IDXX) Five Years Ago Would Have Delivered You a 162% Gain

Investing in IDEXX Laboratories (NASDAQ:IDXX) Five Years Ago Would Have Delivered You a 162% Gain

五年前投資IDEXX實驗室(納斯達克股票代碼:IDXX)將爲您帶來162%的收益
Simply Wall St ·  01/30 08:24

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But when you pick a company that is really flourishing, you can make more than 100%. Long term IDEXX Laboratories, Inc. (NASDAQ:IDXX) shareholders would be well aware of this, since the stock is up 162% in five years. Also pleasing for shareholders was the 33% gain in the last three months. But this could be related to the strong market, which is up 18% in the last three months.

在買入公司股票(假設沒有槓桿作用)之後,最糟糕的結果是你損失了所有投入的錢。但是,當你選擇一家真正蓬勃發展的公司時,你可以 使 超過 100%。IDEXX Laboratories, Inc.(納斯達克股票代碼:IDXX)的長期股東會意識到這一點,因爲該股在五年內上漲了162%。同樣令股東高興的是,過去三個月的漲幅爲33%。但這可能與強勁的市場有關,市場在過去三個月中上漲了18%。

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

考慮到這一點,值得一看公司的基本面是否是長期業績的驅動力,或者是否存在一些差異。

See our latest analysis for IDEXX Laboratories

查看我們對 IDEXX 實驗室的最新分析

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

不可否認,市場有時是有效的,但價格並不總是能反映潛在的業務表現。通過比較每股收益(EPS)和一段時間內的股價變化,我們可以了解投資者對公司的態度是如何隨着時間的推移而變化的。

During five years of share price growth, IDEXX Laboratories achieved compound earnings per share (EPS) growth of 21% per year. This EPS growth is remarkably close to the 21% average annual increase in the share price. Therefore one could conclude that sentiment towards the shares hasn't morphed very much. In fact, the share price seems to largely reflect the EPS growth.

在五年的股價增長中,IDEXX實驗室實現了每年21%的複合每股收益(EPS)增長。每股收益的增長非常接近股價年均增長21%。因此,人們可以得出結論,對股票的情緒並沒有太大變化。實際上,股價似乎在很大程度上反映了每股收益的增長。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下圖中看到 EPS 隨時間推移的變化(點擊圖表查看確切值)。

earnings-per-share-growth
NasdaqGS:IDXX Earnings Per Share Growth January 30th 2024
納斯達克GS:IDXX 每股收益增長 2024 年 1 月 30 日

We know that IDEXX Laboratories has improved its bottom line lately, but is it going to grow revenue? If you're interested, you could check this free report showing consensus revenue forecasts.

我們知道IDEXX Laboratories最近提高了利潤,但它會增加收入嗎?如果你感興趣,可以查看這份顯示共識收入預測的免費報告。

A Different Perspective

不同的視角

IDEXX Laboratories shareholders gained a total return of 10% during the year. But that was short of the market average. If we look back over five years, the returns are even better, coming in at 21% per year for five years. It may well be that this is a business worth popping on the watching, given the continuing positive reception, over time, from the market. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 1 warning sign for IDEXX Laboratories that you should be aware of before investing here.

IDEXX實驗室的股東在年內獲得了10%的總回報。但這低於市場平均水平。如果我們回顧五年,回報率甚至更高,五年內每年爲21%。鑑於隨着時間的推移,市場持續給予積極的歡迎,這很可能是一項值得關注的業務。我發現將長期股價視爲業務績效的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,我們發現了IDEXX實驗室的1個警告信號,在這裏投資之前,您應該注意這一點。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,請看一下我們預計收益將增加的這份免費公司名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論